Press Releases Press Releases Year None202020192018 May 15, 2020 Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates May 12, 2020 Stoke Therapeutics Presents Preclinical Data That Demonstrate In-Vitro and In-Vivo Target Engagement and Protein Upregulation in OPA1 Protein Deficiency, the Primary Cause of the Most Common Inherited Optic Nerve Disorder March 23, 2020 Stoke Therapeutics Reports Full Year 2019 Financial Results and Provides Business Updates February 24, 2020 Stoke Therapeutics to Present at 40th Annual Cowen Health Care Conference January 7, 2020 Stoke Therapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference Toolkit Print Page Email Alerts Contact IR FAQ
Press Releases Year None202020192018 May 15, 2020 Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates May 12, 2020 Stoke Therapeutics Presents Preclinical Data That Demonstrate In-Vitro and In-Vivo Target Engagement and Protein Upregulation in OPA1 Protein Deficiency, the Primary Cause of the Most Common Inherited Optic Nerve Disorder March 23, 2020 Stoke Therapeutics Reports Full Year 2019 Financial Results and Provides Business Updates February 24, 2020 Stoke Therapeutics to Present at 40th Annual Cowen Health Care Conference January 7, 2020 Stoke Therapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference
May 15, 2020 Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
May 12, 2020 Stoke Therapeutics Presents Preclinical Data That Demonstrate In-Vitro and In-Vivo Target Engagement and Protein Upregulation in OPA1 Protein Deficiency, the Primary Cause of the Most Common Inherited Optic Nerve Disorder
March 23, 2020 Stoke Therapeutics Reports Full Year 2019 Financial Results and Provides Business Updates